Jing Yu, Zhuoyue Shi, Hengwei Wu, Yi Luo, Jian Yu, Yamin Tan, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Yishan Ye, Luxin Yang, Congxiao Zhang, He Huang, Jimin Shi, Yanmin Zhao
{"title":"体重指数对接受同种异体造血干细胞移植的急性白血病患者预后的影响:一项回顾性队列研究","authors":"Jing Yu, Zhuoyue Shi, Hengwei Wu, Yi Luo, Jian Yu, Yamin Tan, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Yishan Ye, Luxin Yang, Congxiao Zhang, He Huang, Jimin Shi, Yanmin Zhao","doi":"10.1177/09636897251349377","DOIUrl":null,"url":null,"abstract":"<p><p>Obesity is a well-known risk factor for many diseases, but the impact of baseline body mass index (BMI) on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains controversial. To elucidate the influence of pretransplant BMI on post-allo-HSCT outcomes including graft-versus-host disease (GVHD), overall survival (OS), relapse-free survival (RFS), and nonrelapse mortality (NRM), we conducted a retrospective study using registry data which comprised 1092 adult patients who underwent allo-HSCT between 2015 and 2023. Among the 1092 eligible patients (53.2% male), 56.5% were normal-weight; 24.8% were overweight and 9.1% were obese. Multivariable analyses revealed that compared with normal-weight patients, obese individuals had a higher risk of grade II-IV and III-IV acute GVHD (aGVHD), especially in the gastrointestinal system, with aHRs of 2.08 (95% CI, 1.47-2.94), 2.60 (95% CI, 1.52-4.44), and 3.71 (95% CI, 2.00-6.88), respectively. The probability of OS and RFS was significantly lower in overweight (<i>P</i> = 0.034, <i>P</i> = 0.015, respectively) and obese patients (<i>P</i> = 0.033, <i>P</i> = 0.024, respectively) as compared with normal-weight patients, with aHRs increasing by ~38% (aHR, 1.38; 95% CI, 1.03-1.86), ~40% (aHR, 1.40; 95% CI, 1.07-1.83), ~58% (aHR, 1.58; 95% CI, 1.04-2.40), and ~56% (aHR, 1.56; 95% CI, 1.06-2.29), respectively. Furthermore, the NRM of obese patients was statistically higher than normal-weight patients (<i>P</i> = 0.02, sHR, 2.19; 95% CI, 1.12-4.27). A subgroup analysis revealed that the adverse effects of obesity on OS, RFS, and NRM were primarily observed in the subgroup of patients aged < 40 years and patients with acute lymphoblastic leukemia. The increased risk of grade II-IV aGVHD due to obesity was observed across all subgroups. In conclusion, Obesity prior to allo-HSCT increases the risk of aGVHD and NRM, leading to poorer OS. These findings underscore the importance of closely monitoring high-risk patients and offering opportunities for early intervention.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"34 ","pages":"9636897251349377"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198581/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prognostic effect of body mass index in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation: A retrospective cohort study.\",\"authors\":\"Jing Yu, Zhuoyue Shi, Hengwei Wu, Yi Luo, Jian Yu, Yamin Tan, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Yishan Ye, Luxin Yang, Congxiao Zhang, He Huang, Jimin Shi, Yanmin Zhao\",\"doi\":\"10.1177/09636897251349377\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Obesity is a well-known risk factor for many diseases, but the impact of baseline body mass index (BMI) on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains controversial. To elucidate the influence of pretransplant BMI on post-allo-HSCT outcomes including graft-versus-host disease (GVHD), overall survival (OS), relapse-free survival (RFS), and nonrelapse mortality (NRM), we conducted a retrospective study using registry data which comprised 1092 adult patients who underwent allo-HSCT between 2015 and 2023. Among the 1092 eligible patients (53.2% male), 56.5% were normal-weight; 24.8% were overweight and 9.1% were obese. Multivariable analyses revealed that compared with normal-weight patients, obese individuals had a higher risk of grade II-IV and III-IV acute GVHD (aGVHD), especially in the gastrointestinal system, with aHRs of 2.08 (95% CI, 1.47-2.94), 2.60 (95% CI, 1.52-4.44), and 3.71 (95% CI, 2.00-6.88), respectively. The probability of OS and RFS was significantly lower in overweight (<i>P</i> = 0.034, <i>P</i> = 0.015, respectively) and obese patients (<i>P</i> = 0.033, <i>P</i> = 0.024, respectively) as compared with normal-weight patients, with aHRs increasing by ~38% (aHR, 1.38; 95% CI, 1.03-1.86), ~40% (aHR, 1.40; 95% CI, 1.07-1.83), ~58% (aHR, 1.58; 95% CI, 1.04-2.40), and ~56% (aHR, 1.56; 95% CI, 1.06-2.29), respectively. Furthermore, the NRM of obese patients was statistically higher than normal-weight patients (<i>P</i> = 0.02, sHR, 2.19; 95% CI, 1.12-4.27). A subgroup analysis revealed that the adverse effects of obesity on OS, RFS, and NRM were primarily observed in the subgroup of patients aged < 40 years and patients with acute lymphoblastic leukemia. The increased risk of grade II-IV aGVHD due to obesity was observed across all subgroups. In conclusion, Obesity prior to allo-HSCT increases the risk of aGVHD and NRM, leading to poorer OS. These findings underscore the importance of closely monitoring high-risk patients and offering opportunities for early intervention.</p>\",\"PeriodicalId\":9721,\"journal\":{\"name\":\"Cell Transplantation\",\"volume\":\"34 \",\"pages\":\"9636897251349377\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198581/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/09636897251349377\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CELL & TISSUE ENGINEERING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/09636897251349377","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
Prognostic effect of body mass index in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation: A retrospective cohort study.
Obesity is a well-known risk factor for many diseases, but the impact of baseline body mass index (BMI) on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains controversial. To elucidate the influence of pretransplant BMI on post-allo-HSCT outcomes including graft-versus-host disease (GVHD), overall survival (OS), relapse-free survival (RFS), and nonrelapse mortality (NRM), we conducted a retrospective study using registry data which comprised 1092 adult patients who underwent allo-HSCT between 2015 and 2023. Among the 1092 eligible patients (53.2% male), 56.5% were normal-weight; 24.8% were overweight and 9.1% were obese. Multivariable analyses revealed that compared with normal-weight patients, obese individuals had a higher risk of grade II-IV and III-IV acute GVHD (aGVHD), especially in the gastrointestinal system, with aHRs of 2.08 (95% CI, 1.47-2.94), 2.60 (95% CI, 1.52-4.44), and 3.71 (95% CI, 2.00-6.88), respectively. The probability of OS and RFS was significantly lower in overweight (P = 0.034, P = 0.015, respectively) and obese patients (P = 0.033, P = 0.024, respectively) as compared with normal-weight patients, with aHRs increasing by ~38% (aHR, 1.38; 95% CI, 1.03-1.86), ~40% (aHR, 1.40; 95% CI, 1.07-1.83), ~58% (aHR, 1.58; 95% CI, 1.04-2.40), and ~56% (aHR, 1.56; 95% CI, 1.06-2.29), respectively. Furthermore, the NRM of obese patients was statistically higher than normal-weight patients (P = 0.02, sHR, 2.19; 95% CI, 1.12-4.27). A subgroup analysis revealed that the adverse effects of obesity on OS, RFS, and NRM were primarily observed in the subgroup of patients aged < 40 years and patients with acute lymphoblastic leukemia. The increased risk of grade II-IV aGVHD due to obesity was observed across all subgroups. In conclusion, Obesity prior to allo-HSCT increases the risk of aGVHD and NRM, leading to poorer OS. These findings underscore the importance of closely monitoring high-risk patients and offering opportunities for early intervention.
期刊介绍:
Cell Transplantation, The Regenerative Medicine Journal is an open access, peer reviewed journal that is published 12 times annually. Cell Transplantation is a multi-disciplinary forum for publication of articles on cell transplantation and its applications to human diseases. Articles focus on a myriad of topics including the physiological, medical, pre-clinical, tissue engineering, stem cell, and device-oriented aspects of the nervous, endocrine, cardiovascular, and endothelial systems, as well as genetically engineered cells. Cell Transplantation also reports on relevant technological advances, clinical studies, and regulatory considerations related to the implantation of cells into the body in order to provide complete coverage of the field.